Varenicline occupies the neuronal nicotinic α₄β₂ receptor but activates it only partly, so beside a full agonist like Nicotine gum it behaves as a brake.
Nicotine gum is a full agonist at the neuronal nicotinic α₄β₂ receptor. Varenicline binds the same receptor but produces a submaximal response however much of it is present. On an unoccupied receptor it acts; on a receptor already driven by Nicotine gum it displaces that fuller signal and the net effect falls.
Given together they work against whatever each was started for. If both are genuinely needed, expect less of Nicotine gum’s effect than its dose would suggest.
This is a pharmacodynamic interaction. Neither drug changes the other’s concentration, so a level, an AUC estimate or a genotype looks entirely normal while the clinical effect is blunted.
The direction can be the useful one. The same opposition is what makes a reversal agent, an antidote or a planned antagonist work.



The ring marks the peg each drug wears for this receptor — the same cross-illumination Interact! draws when the two are put side by side.

